Introduction
============

Cone Beam Computed Tomography (CBCT) imaging has become increasingly important during lung navigated interventions, demonstrating a fact that is correlated with modern endoscopic and image-guided diagnostic and/or therapeutic modalities addressing thoracic malignancies.[@B1]-[@B11] First reports on medical navigation during thoracic surgical procedures such as from the SHG Hospital Voelklingen, Germany and University Hospital, Saga, Japan (Customer Magazine AXIOM Innovations November, 2012) paved the way to advanced thoracic operative theaters in that they allow multimodal interventional approaches. However CBCT navigation carries an additional radiation exposure to patient and operator, which has not been measured or published for lung procedures to this day. Modern CBCT configurations allow the standard 2-dimensional (2D) projection functionality like fluoroscopy as well as volumetric computed tomography (CT) capabilities within the interventional suite. For acquisition of the 3-dimensional (3D) dataset the C-arm of CBCT needs to rotate by at least 200° (180° plus fan angle) around the target that has to remain stationary during acquisition.[@B12] For our lung image acquisition we use the 5 seconds (s) run with 248 single 2D-projections with a 30cm\*40cm head. Our protocol is providing sufficient image quality for clearly displaying the bronchial structures as well as the target itself. (Figure [1](#F1){ref-type="fig"}) These data are sent automatically to a workstation where the reconstruction is completed within less than 15s. At the workstation the target itself as well as the path within the bronchial tree are identified and marked with manual annotation tools (Siemens iguide toolbox). Afterwards these markers are projected and overlaid to the fluoroscopic image. (Figure [2](#F2){ref-type="fig"}) This technique allows the physician to match his instruments to the overlay and in consequence navigate correctly to the (sometimes fluoroscopy-invisible) target. The major limitation of this technique is significantly poorer image quality if there is target motion during 3D acquisition. For eliminating this factor the absence of spontaneous respiration is mandatory - the patient has to be put into apnea. The connected jet ventilation system (TwinStream, Carl Reiner, and Austria) is maintaining the inspiration phase during acquisition and navigation process. This leads to an accurate match between the 3D dataset and the fluoroscopic image. At the same time maintained inspiratory ventilator set-up with high inspiratory pressures (e.g. at least over 2,5bar) over e.g. 12s hyperinflates the lung. This offers good visualization of bronchioli smaller 3mm in diameter after the 7^th^-8th segmentation. (Figure [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}) When used in normofrequent jet-ventilation (e.g. jet-ventilation with respiratory frequency (RF) 80/min with inspiration-exspiration ratio (I: E) of 1:1,5) standard inspiratory working pressures (SIWP) initially are set up along the weight of a patient: (SIWP) (bar) = (weight (kg)\*0,015) with a fractional inspiratory oxygen concentration (FIO2) 0,8-1. To perform 3D data acquisition under hyperinflation it is necessary to change the set-up of the ventilator to RF 2/min with an I: E 3:1 giving at least 15s of maintained hyperinflation without any movement: During this period there is perfect alignment between the virtual anatomy derived from the 3D data acquisition overlaid in fluoro imaging and the real anatomy. To reach the optimal hyperinflation the SIWP is elevated in steps of 0,5bar until a peak inspiratory pressure (PIP) measured at the tip of the double lumen jet-catheter (Acutronic, Medical Systems, Switzerland) reaches 40mbar. (Figure [5](#F5){ref-type="fig"}) The positioning of the jet-catheter is performed by seldinger technique with use of a pulmonary jag-wire (Boston Scientific, USA).

Materials and Methods for radiation exposure measurements
=========================================================

The male Alderson-Rando phantom (The Phantom RANDO^®^, Alderson Research Laboratories Inc., Stamford, CT, USA) (mARp) is an anthropomorphic phantom which can be equipped with dosimeters. (Figure [6](#F6){ref-type="fig"}.) It consists of a human skeleton which is embedded in a rubber composition with isocyanate having a specific density of 0.985 g/cm ³ along with absorption and scattering properties to X-rays equivalent to those of the human tissue.

The height of the limb-less body phantom is 173 cm, its weight amounts 73.5 kg. The sagittal diameter of the abdomen measures 22 cm. The phantom can be disassembled into 2.5 cm thick, axial slices. Each layer is provided with holes meant for holding dosimeters. These dosimeters are thermoluminescense detectors (TLD). These detectors are based on the emission of thermoluminscence (TL) on heating of previously exposed crystalline materials. The intensity of the emitted TL is a function of the dose deposited in the material, and can therefore be used for dosimetry.

Calibration of TLD
------------------

In TLD with the same time-radiation history i.e. always irradiated, analyzed and regenerated together at the same time, the change in the calibration factor is approximately equal.

Therefore, the TLDs are summarized in batches which always pass together through a measurement cycle. A batch is always divided into two fractions during a measurement. The first fraction (F1) is subjected to a calibration irradiation at a defined dose (1 Gy) to determine the change in the calibration factor. This change of calibration factor can be applied to the second fraction (F2) which is used for the actual measurement of the radiation dose.

As a TLD for the organ dose measurements serves Lithium-Fluorid-thermoluminescence dosimeters (The Harshaw Chemical Company, Chrystal and Electronics Products Department, Solon, Ohio, USA) (TLD-100 rods, 1 x 1 x 6 mm). The locations are selected on the basis of a CT atlas. Three TLD rods were packed in plexiglass tube and then inserted into the corresponding holes of the respective layer of the mARp. For dose measurements with the mARp 150 TLDs were fitted to 43 different measuring points.

TLD-Reader
----------

The TLD rods were stabilized C (\"pre-annealing\") and analysed in the next hours following the investigation for 10min at 100°. The TLD reader used is an analyzer type Harshaw. For these analyses the TLDs are placed in an evaluation unit which provides at the same time for heating and for transmitted light detection during the heating process. For light detection photomultiplier (PM) are used. The electric current generated by transmitted light during the heating process is proportional to the amount of light emitted from the TLD. Before each measurement a current measurement under dark conditions is carried out to ensure a constant PM sensitivity. The dosimeters are heated in 20 s with a linear increase in temperature to 270°C. The measured values ​​are adjusted by the background radiation, which is determined by fraction F1 of each TLD-rod batch. Each organ dose results from the average of the adjusted data from the three TLD rods per measurement point. A backscatter correction of the measured values ​​for the dose is performed. From the different measured values of organ doses finally the effective patient dose is calculated.

Calculation of the effective patient dose
-----------------------------------------

The effective dose (otherwise known as the effective dose equivalent) is a measure of radiation exposure of humans. To calculate the effective dose (Deff) the organ doses (HT) are multiplied by the tissue weighting factor (wT) of each organ (T). The sum of such weighted organ doses results in the effective (whole body) dose in Sievert (Sv):

The tissue weighting factors were used by us in accordance with the current recommendations of the International Commission on Radiological Protection (IRCP). [@B13] The dose-area product has been stored for the entire investigation.

Dose-Area product (DAP)
-----------------------

The DAP was recorded using a panel attached to the ionization measurement chamber and by a reader (Diamentor M3, PTW, Freiburg, Germany) the value appeared in \"cGycm²\".

It is calculated by multiplying the ionization in air (air kerma \[cGy\]) in the measurement chamber with the irradiated area \[cm²\]. The DAP and the fluoroscopy time were recorded separately for the above mentioned subsequent simulated investigation over 20min. Furthermore, the kV and mA values ​​were recorded.

Our standard protocol of specific jet-ventilation with deep sedation in complete apnea for the purpose of CBCT guided endobronchial navigation consists of the following steps:Seldinger-technique for jet-catheter positioning in the middle part of the trachea.Initiation of sedation protocol to achieve very low frequency of spontaneous breathing near apnea with remifentanil- (0,05ug/kg/min) and propofol-perfusors (4mg/kg/h). For definite apnea during data acquisition we used additional boli of 50mg propofol. In case of low blood pressure we applied saline 0,9% and sometimes akrinor (Ratiopharm, Germany; 2ml consists of cafedrinhydrochlorid 200mg and theodrenalinhydrochlorid 10mg as main drugs), in case of low heart frequency less than 50/min we applied atropine (B. Braun, Germany; 0,5mg/ml).Bronchoscopic control of the jet-catheter position after nasal fixation to avoid direct objection against any endoluminal obstacle and introduction of an oral Guedel tube to keep pharynx and mouth open.Application of the above mentioned low frequency inversed ratio jet-catheter set-up with FIO2 100% and uptitration of the SIWP up to a PIP of 40mbar. The maximum allowed SIWP is 3,5bar. By this means we achieve maximal tolerable hyperinfiltration.Establishing complete apnea by the use of additional propofol boli for data acquisition under constant hyperinflation with CBCT.Annotation of the path and the target with the Siemens toolbox and overlay of this 3D-information in the fluoroscopy image.In a situation of navigational decision the same ventilator set-up as during data acquisition has to be applied in order to guarantee perfect alignment of the virtual path and target volume with natural anatomy.Navigation control is achieved by the so called 3-edges-angulation during this period of perfect alignment. From a posterior-anterior position of the DynaCT-head one has to angulate thirty degrees lateral, then follow with another angulation of thirty degrees caudal or cranial and finally angulate thirty degrees medial. (Figure [7](#F7){ref-type="fig"}.) The examiner has to compare these 3 views of the used endobronchial probe under fluoroscopy with the virtual anatomy overlaid in the fluoroscopy image: If we observe that the probe in all views stays in the virtual path segmentation or the target volume we can conclude that it has reached the desired anatomical position endothoracically. The number of 3-edges angulations needed depends on the complexity of the path and the endoluminal entry into the target. During the examination time when no navigational decision is needed we apply normofrequent jet-ventilation (e.g. RF 80/min; I: E 1:1, 5; SIWP in regards to blood gases).Biopsy is performed within the second of the manual stop of the ventilator set-up to avoid peripheral pneumothorax under hyperinflation. Repeated biopsies are done without additional 3-edges-angulations via an applied sheath which was used with first biopsy put over the instrument.

Results
=======

With the following standard program on our ceiling-mounted Artis Zee we found a whole body effective radiation dose of 0,98mSv under CBCT data acquisition for a SPN in the RUL. Adding 4 maneuvers of endobronchial lung navigation towards a SPN after the 8^th^ segmentation in the RUL over 20min this dose increased to 1,15mSv for acquisition and navigation. (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"})

Coro 40 Log Dyna CT Cardiac; 5sec untriggered; 91kV,344mA, 3,9ms,1859,9µGym², 62,6mGy: 0,98-1,15 mSv

Discussion
==========

There is a high need for navigation in the lung to improve the diagnostic yield for SPNs, especially for SPNs \< 3 cm or for fluoroscopy transparent nodules [@B14] where conventional bronchoscopy shows very limited diagnostic yield. This is in contrast to the fact that the principle rule\'\' the earlier the diagnosis, the better the prognosis of an oncologic disease\'\' especially counts for the size of an incidental lung cancer according to current guidelines.[@B15] Different electromagnetical navigation (EMN) techniques for endobronchial approach have been developed in the last years aiming to improve the diagnostic yield. They are based on a low power magnetic resonance field in which the patient with magnetic sensors fitted instruments is explored by the help of a preceeding CT-data-acquisition.[@B16]-[@B19] This preceeding CT-dataset is overlaid and corrected by typical landmarks (e.g. carinas) of the existing anatomy given by realtime bronchoscopy views. By this fusion and the identification of the instrument position in the 3-dimensional volume this technique can produce \'\'realtime\'\' virtual anatomy pictures beyond central airways which is then processed in a way to increase the ability of examiners to reach distal SPNs. It has been shown that EMN bronchoscopy provides a superior diagnostic yield of 59-74% in SPN compared to standard transbronchial biopsy with an acceptable rate of complications mainly pneumothorax. [@B16]-[@B23] Diagnostic yield can be increased if a radial ultrasound probe is used to visualize the lesion and therefore prove that the tip of the extended working channel ends in the target zone. [@B16] An additional CT has to be performed as most of the CT scans during the initial diagnostic work-up do not fulfill the criteria necessary for EMN systems. In the end an EMN procedure is a 2-steps method: Data acquisition does not take place in the same examination set-up as for taking biopsies or local treatment. Most EMN systems do not offer a transthoracical approach. High acquisition and maintenance costs prevent a wide spread of this technique until now. From our view there are the following substantial differences between 2-steps EMN methods and real-time extrathoracical 1-step CBCT-navigation:

Firstly, in EMN bronchoscopy the essential preceding CT-dataset is an additional radiation exposure for the patient which is higher than the radiation exposure by CBCT navigation in average (Table [3](#T3){ref-type="table"},[4](#T4){ref-type="table"},[5](#T5){ref-type="table"},[6](#T6){ref-type="table"},[7](#T7){ref-type="table"}.) Secondly, the major disadvantage of a 2 steps-method is the fact that the preceeding CT-dataset is made during deep inspiration bending down the diaphragm for a susbtantial height of several centimeters especially for SPNs in the lower lobes. This position of the diaphragm is completely different to the situation under conventional or navigated bronchoscopy by the help of the above mentioned systems as bronchoscopies are performed under deep sedation in reduced spontaneous breathing pattern which normally elevates the diaphragm until the functional residual capacity of the patient\'s lung is reached. This means a great difference between the preceeding dataset and real-time true anatomy due to diaphragm recoil. Although there are efforts in some EMN systems (like Veran Technology) to compensate respiratory movement during navigation it is still a 2-steps method. Thirdly, the proceeding CT-dataset is not performed on the same table at the same time in the same organ and patient position in the same place as with our protocol with CBCT. In case there is no organ and patient movement there is in principal perfect alignment of virtual 3D-dataset of CBCT-acquisition and realtime true anatomical positon during endobronchial navigation. Moreover; extrathoracical navigation by CBCT for endobronchial purpose is delivering the possibility of using the \'\'unoccupied\'\' working channel of bronchoscopes for conventional instruments. Our method with CBCT can perform continous endobronchial guidance and at the same time allow regular bronchoscopy performances and maybe in future endobronchially driven ablative local therapies. Furthermore, EMN navigation does not offer a CT-similar function for transthoracical approach as CBCT does: One may choose in regards to the localisation of a SPN the access - endobronchial or transthoracical. Concerning additional radiation exposure to patients the hereby first time measured effective whole body radiation dose as mentioned above is in comparison to other CT-applications in chest medicine a very low figure. Possible explanations for this very low figure could be attributed to the following:

Firstly, an excentric patient position for imaging of one (right) lung which would have induced less radiation exposure. During our simulation at the phantom we clearly averted this faulty position. Sencondly, in MSCT-acquisition the whole body diameter of a patient is exposed to radiation which is not true for CBCT-acquisition: The restriction by the geometry of the flat panel detector and the zoom-factor causes the so called field of view which is a cylindric volume of a certain diameter smaller than the normal whole body volume. This reduces again radiation exposure. Thirdly, as the most navigation cases take place in the right lung the dose measurements were performed for right lung upper field. One has to remember that effective dose is based on x-ray sensitivity of organs. Right lung is located away from stomach (with tissue factor 0,12) and close to liver (tissue factor 0,05). This makes in the end a reduction of a few percentages of the whole body effective radiation dose. Compared to other thoracic CBCT applications such dose is quite low [@B24] and allows from a radiation hygienic point of view to use this technique generously for evaluation and treatment of thoracic lesions. This dose is at least 1/3 less than the dose that was used in the National Lung Screening Trial (NLST) in the United States.[@B25] Compared to conventional CT guidance for transthoracic approaches CBCT navigation reduces the radiation exposure up to 42% during transcutaneous approach.[@B26] The use of endobronchial navigation for bronchoscopic tissue biopsy in a conventional multi-slice CT with low-dose protocols (MDCT) is comparable in radiation effective organ doses to patient.[@B27], [@B28] (Table [3](#T3){ref-type="table"}.) Conversely to the closed MDCT configuration, the open CBCT structure allows for an easy access to the patient giving an advantage in coping with possible interventional complications. The hereby first time described technique has the potential to improve the determination and treatment of smaller incidental solitary pulmonary nodule (SPN) that are partially invisible under conventional fluoroscopy compared to the results of conventional bronchoscopy. [@B14] In the future we believe that CBCT guided interventions will be the standard of care for any kind of focal procedures like endoluminal or endovascular navigation, transthoracical or endoluminal thermal ablation, local chemotherapy or other minimal-invasive procedures - in surgical or non-surgical interventional settings. Besides the above mentioned approaches in CBCT guided thoracical surgery some approaches have been made in the last years in different new therapeutic fields [@B1], [@B29]. Very recently the combination of electromagnetic navigation devices and common CT-technology showed higher efficacy in transthoracical lung ablation procedures compared to standard CT-guidance alone [@B30]. One can assume that this combination may improve the qualities of CBCT-guided interventions in future in a similar way. A CBCT-suite should be used by all kinds of interventional departments. Due to his qualities in 2D- and 3D-imaging, fusion capabilities, local flexibility and patient friendly easy-to-access feasibility it will be the central part of hybrid rooms. It may be therefore an instrument to urge different medical specialties to cross over their very individual borders of interventional knowledge in the sense of real translational medicine: Get together in the CBCT-suite and take the best of all interventional worlds.

Conclusions
===========

CBCT with DynaCT Artis Ceiling system for endobronchial navigation in the lung is adding a comparable low radiation exposure to the diagnostic process of possible malignancy in the lung. It is offering some unique features like 1-step method of acquiring and applying the 3-dimensional dataset at the same time on the same table in the same place in comparison to EMN techniques. As an extrathoracical approach this system can be used to control as well therapeutic procedures endobronchially or transthoracically performed under realtime guidance. The open structure of a DynaCT is another advantage over closed MDCT-navigation-systems. Therefore the high feasibility as true multifunctional realtime navigation tool for diagnostic and therapeutic purposes justifies a widespread use even with low additional patient\'s radiation exposure.

![A) DynaCT with a bit of motion artefact, B) Right: HRCT 1mm nearly same level; slices same patient (2 adeno-carcinomas: \*) Showing the same nice details (arrows at the same position indication bronchioli of 2mm and less).](jcav05p0192g001){#F1}

![A) DynaCT with carcinoid\*Arrows indicating small bronchioli subpleural. B) Right: iguide toolbox with the same dataset before annotation of the path and target volume.](jcav05p0192g002){#F2}

![A) Dotting the pathway in the 3 standard axis, B) Segmentation and dotting of the SPN in the 3 standard axis, C) Overlay in fluoroscopy (different patients).](jcav05p0192g003){#F3}

![An example of navigation up to a SPN after the 8th segmentation (counted from the main carina).](jcav05p0192g004){#F4}

![Jet-catheter inserted in trachea in DynaCT (arrows).](jcav05p0192g005){#F5}

![The male Rando Alderson phantom 3edge angulations with 3 different views at least 30 degrees different to each other and with one oblique view.](jcav05p0192g006){#F6}

![3edge angulations with 3 different views at least 30 degrees different to each other and with one oblique view.](jcav05p0192g007){#F7}

###### 

Measured radiation doses in the mARp during acquisition.

  Organ             Organ dose (mSv)   Weighting factor   Effective dose (mSv)
  ----------------- ------------------ ------------------ ----------------------
  brain             0,14               0,01               0,001
  thyroid           1,03               0,04               0,041
  lung              3,53               0,12               0,424
  bone marrow       1,94               0,12               0,233
  esophagus         4,47               0,04               0,179
  thymus            4,00               0,01               0,040
  breast            0,00               0,12               0,000
  liver             0,14               0,04               0,006
  stomach           0,11               0,12               0,013
  spleen            0,05               0,01               0,001
  adrenal glands    0,15               0,01               0,002
  pancreas          0,12               0,01               0,001
  left kidney       0,07               0,01               0,001
  small intestine   0,00               0,01               0,000
  colon             0,00               0,12               0,000
  ilopsoas muscle   0,00               0,01               0,000
  ovar / testes     0,00               0,08               0,000
  uterus            0,00               0,01               0,000
  bladder           0,00               0,04               0,000
  bone surface      0,38               0,01               0,004
  skin              0,40               0,01               0,004
  other organs      0,56               0,06               0,034
  **total**                            **1,00**           **0,982**

###### 

Measured radiation doses in the mARp during acquisition and 4 navigation maneuvers towards a SPN in the RUL after the 8^th^segmentation.

  ----------------- ------ ---------- -----------
  brain             0,17   0,01       0,002
  thyroid           6,34   0,04       0,254
  **lung**          3,18   0,12       **0,382**
  bone marrow       1,83   0,12       0,220
  esophagus         4,48   0,04       0,179
  thymus            4,86   0,01       0,042
  breast            0,00   0,12       0,000
  liver             0,10   0,04       0,004
  stomach           0,08   0,12       0,010
  spleen            0,03   0,01       0,000
  adrenal glands    0,05   0,01       0,000
  pancreas          0,08   0,01       0,001
  left kidney       0,05   0,01       0,000
  small intestine   0,03   0,01       0,000
  colon             0,03   0,12       0,004
  ilopsoas muscle   0,03   0,01       0,000
  ovar / testes     0,06   0,08       0,005
  uterus            0,00   0,01       0,000
  bladder           0,01   0,04       0,000
  bone surface      0,28   0,01       0,003
  skin              0,30   0,01       0,003
  other organs      0,66   0,06       0,041
  **total**                **1,00**   **1,147**
  ----------------- ------ ---------- -----------

###### 

Examples of (mean) effective total body doses in examination types of heart, lung, head and abdomen (soft tissue) with CBCT or conventional XR- or CT-technique.

  -----------------------------------------------------------------------------------------------------------------------
  Examination type                                                             mean eff. patient dose (mSv)   Ref.
  ---------------------------------------------------------------------------- ------------------------------ -----------
  Heart (EP), 30cm\*40cm head CBCT (biplane)\                                  6,6                            24
  (only 3D-data acquisition)                                                                                  

  Heart (EP), XR guided                                                        8,3 (per hour)                 7

  Heart (EP), XR guided, normal weight                                         15,2 (per 5,3 hour)            8

  Heart (EP), XR guided, overweight                                            26,7 (per 5,3 hour)            8

  Heart (EP), XR guided, obese                                                 39,0 (per 5,3 hour)            8

  Lung (MDCT) (\*)                                                             2                              12

  Lung (standard thoracic CT, MSCT)                                            7-8                            11,12,26

  Triple-rule-out CT-angiography, 256-MSCT                                     6,5(male)-3,8(female)          6

  Head protocol, CBCT (2 different systems)                                    4,4-5,4                        9

  Head protocol, MDCT                                                          4,3                            9

  Abdomen, 2 protocols each, CBCT (2 different systems)                        15-37                          9

  Abdomen, 2 protocols, MDCT                                                   9,8-13,5                       9

  Percutaneous transthoracic needle biopsy of pulmonary nodules \< 1cm, CBCT   5,72mSv                        10

  Endobronchial lung navigation (MDCT)                                         0,55-0,7                       28

  Endobronchial lung navigation, 30cm\*40cm head CBCT                          0,98-1,15                      our study
  -----------------------------------------------------------------------------------------------------------------------

EP: Electrophysiology. XR: Fluorscopy. (\*) National Lung Screening Trial in the USA. MSCT (multiple slice CT). MDCT (multiple slice low-dose CT).

###### 

Examples of mean effective patient doses in milisievert (mSv) in classical XR-guided interventions consisting of radiography and repeated fluoroscopy.

  Examination type                 Radiography   Fluoroscopy   Total radiation exposure
  -------------------------------- ------------- ------------- --------------------------
  Abdominal angiography            3,1           5,1           8,2
  Arteriography of lower limbs     3,8           2,4           6,2
  Biliary drainage                 1,8           36,4          38,2
  Embolization of spermatic vein   0,4           16,9          17,3
  Nephrostomy                      0,9           12,7          13,6

###### 

Effective doses of different organs in orthopedics / trauma surgery: Comparison of conventional XR guided approach vs. CBCT-navigated approach.

  Spine surgery     Sacroiliac joint                  
  ----------------- ------------------ ------- ------ -------
  ovar              0,03               0,97    0,45   4,59
  testis            0,04               0,83    0,16   0,79
  red bone marrow   0,61               22,48   2,31   14,39
  sigmoid/Rectum    0,05               2,22    1,23   3,24
  lung              0,03               0,17    0,04   0,14
  stomach           1,55               8,28    0,08   0,23
  bladder           0,07               3,47    0,32   1,88
  liver             1,18               3,30    0,07   0,33
  esophagus         0,02               0,09    0,04   0,08
  thyroid           0,00               0,09    0,01   0,02
  Bone surface      0,46               1,68    0,16   0,79
  others            1,02               10,47   0,38   1,14
  Adrenal gland     1,15               4,68    0,10   0,40
  brain             0,00               0,02    0,00   0,03
  small bowel       1,43               31,14   0,28   0,92
  kidney            1,79               13,26   2,35   0,74
  pancreas          1,09               4,79    0,09   0,30
  spleen            2,59               16,96   0,16   0,43
  thymus            0,00               0,06    0,02   0,06
  colon             1,16               22,32   2,07   2,82

###### 

Effective total body doses in different phantoms on a biplane CBCT.

             Programs on Axiom Artis, syngo DynaCT 20\*20cm2 biplane flat panel CBCT                                   
  ---------- ------------------------------------------------------------------------- ------- ------- ------- ------- -------
  Clifford   0.192                                                                     0.272   0.219   0.326   0.050   0.072
  Braden     0.205                                                                     0.272   0.315   0.392   0.058   0.068
  Alderson                                                                             0.730   0.282                   

The effective dose according to ICRP103 separate for each program, phantom and gender. The values are given in milli Sievert (mSv). Clifford and Braden are hermaphrodite, Alderson is a male phantom. Alderson did not undergo the 5sDRc diagnostic program without grid.

A 10kg model "Clifford" represents children with an age of 0.5-3 years.

A 19kg model "Braden" represents children with an age of 3-7 years.

A 73kg model "Alderson" represents an adult person (as in our study).

###### 

Effective organ doses on Axiom Artis, syngo DynaCT, 20\*20cm2 biplane flat panel CBCT in different phantoms.

  Organ/tissue       Clifford   Braden   Alderson                               
  ------------------ ---------- -------- ---------- ------ ------ ------ ------ ------
  brain              0.04       0.03     0.00       0.01   0.02   0.00   0.00   0.01
  thyroid            0.75       0.33     0.19       0.06   0.08   0.03   0.08   0.01
  lung               0.87       1.19     0.23       0.89   1.28   0.23   2.87   1.21
  red bone marrow    0.09       0.12     0.02       0.31   0.47   0.09   1.29   0.51
  esophagus          0.78       0.60     0.20       1.06   1.50   0.32   3.86   1.24
  thymus             0.87       1.10     0.22       0.90   1.25   0.25   1.03   0.45
  breast             0.65       0.88     0.19       0.64   0.83   0.15   \-     \-
  liver              0.03       0.03     0.01       0.03   0.08   0.00   0.17   0.06
  stomach            0.03       0.04     0.01       0.02   0.08   0.00   0.18   0.07
  spleen             0.06       0.10     0.02       0.02   0.06   0.00   0.11   0.02
  adrenal gland      0.07       0.09     0.02       0.03   0.06   0.00   0.19   0.07
  pancreas           0.05       0.12     0.02       0.01   0.08   0.00   0.16   0.05
  left kidney        0.03       0.06     0.00       0.02   0.03   0.00   0.09   0.05
  small intestine    0.02       0.03     0.01       0.00   0.02   0.00   0.00   0.00
  colon              0.01       0.02     0.00       0.00   0.04   0.00   0.01   0.00
  ovary              002        0.02     0.00       0.00   0.00   0.00   0.00   0.00
  testis             0,00       0.00     0.00       0.00   0.00   0.07   0.00   0.00
  uterus             0.01       0.01     0.00       0.00   0.00   0.00   0.00   0.00
  urinary bladder    0.01       0.01     0.00       0.00   0.00   0.00   0.00   0.00
  bone surface       0.05       0.17     0.02       0.00   0.01   0.00   0.99   0.38
  skin               0.05       0.17     0.02       0.00   0.00   0.00   0.98   0.38
  remainder organs   0.15       0.20     0.04       0.12   0.19   0.03   0.20   0.07
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